Allergy testing is crucial for detecting the exact cause of symptoms and enabling healthcare providers to customize treatment plans effectively. The diagnostic methods are categorized into in vivo tests (such as skin prick, intradermal, and patch tests) and in vitro tests (like blood tests conducted in laboratories). The goal of allergy diagnostic tests is to accurately identify allergens, reduce exposure risks, ease symptoms, and minimize complications. Common allergic conditions include those triggered by inhaled substances, food, skin contact, and medications. If not accurately diagnosed or managed, these allergies can impact quality of life. With the increasing prevalence of allergic diseases worldwide, there is a growing need for accurate, accessible, and prompt diagnostic solutions.
The global Allergy Diagnostics market is estimated at US$5.8 billion in 2024 and is projected to reach US$10.7 billion by 2030, with a CAGR of 10.8% during the forecast period 2024-2030. The global allergy diagnostics market is experiencing substantial growth, primarily driven by rising environmental pollution, rapid urbanization, and climate change factors that have significantly increased human exposure to airborne allergens such as dust, pollen, and industrial emissions. This heightened exposure is contributing to a growing prevalence of allergic conditions, including asthma, allergic rhinitis, and various skin allergies.
Urban populations are particularly at risk due to higher pollutant levels, which trigger immune reactions and create a need for early and precise diagnoses. The trend toward remote consultations and telehealth has enhanced access to diagnostic services, while diagnostic firms are broadening their test offerings to cover a wide range of environmental and food allergens. At the same time, increased awareness about allergies and government-supported awareness initiatives are driving greater demand for timely and accurate allergy diagnoses.
This growth is fueled by rapid urbanization, increasing pollution, and a rise in allergic cases. Countries like China, India, and Japan are expanding healthcare access, adopting advanced diagnostic tools, and investing in personalized and minimally invasive testing. Local firms are also implementing strategic initiatives to strengthen their regional presence. The digital transformation and increasing health consciousness are anticipated to drive market expansion in the Asia-Pacific region, making it a crucial area for growth.
Meanwhile, the instruments segment is projected to grow considerably, supported by advancements in automated systems, multiplex testing capabilities, and high diagnostic precision. Instruments like immunoassay analyzers, though more expensive, are increasingly adopted in diagnostic workflows because they offer faster and more accurate results. Their advanced testing capabilities improve operational efficiency, minimize human error, and support more comprehensive and effective allergy management.
The in vivo testing segment is also witnessing notable growth due to its user-friendliness, affordability, and quick results. Skin-prick tests (SPT) and intradermal tests are commonly used to detect immediate allergic reactions to various allergens such as pollen, dust mites, food, and insect venom. In vivo approaches act as an economical first-line screening option, particularly in price-sensitive markets, often succeeded by confirmatory in vitro assessments.
The innovative Component-Resolved Diagnostics (CRD) technology enhances accuracy by pinpointing specific allergenic proteins, which minimizes cross-reactivity issues associated with tests using whole-allergen extracts. The growth of mold due to flooding and the dispersion of pollen during thunderstorms further increase incidents of respiratory allergies, underscoring the urgent requirement for accurate inhaled allergen diagnosis. In contrast, the food allergens segment is anticipated to experience the fastest CAGR of 11.8% during the analysis period 2024-2030. This growth is fueled by the rising incidence of food allergies, especially among children, and the growing demand for timely and accurate diagnostic solutions.
It is further supported by advancements in diagnostic technologies, heightened awareness among healthcare professionals and patients, and stricter food labeling regulations driven by concerns for food safety. Moreover, globalization and the increased consumption of processed foods heighten exposure risks, further driving the need for food allergen testing and contributing to the overall growth of the allergy diagnostics market.
Hospitals and clinics benefit from integrated patient care, high patient volume, advanced resources, and collaboration with allergists, ensuring diagnostic tests are timely, efficient, and precise. On the other hand, the academic research institutes segment is projected to experience the fastest growth rate at a CAGR of 11.5% from 2024 to 2030, fueled by an increased emphasis on translational research into new biomarkers, molecular allergens, and customized diagnostics. These institutions drive innovation in molecular diagnostics and next-generation sequencing, addressing the growing rates of allergies and developing new therapies and diagnostic methods to enhance patient outcomes and allergy management.
Base Year: 2024
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 14+
This product will be delivered within 2-4 business days.
The global Allergy Diagnostics market is estimated at US$5.8 billion in 2024 and is projected to reach US$10.7 billion by 2030, with a CAGR of 10.8% during the forecast period 2024-2030. The global allergy diagnostics market is experiencing substantial growth, primarily driven by rising environmental pollution, rapid urbanization, and climate change factors that have significantly increased human exposure to airborne allergens such as dust, pollen, and industrial emissions. This heightened exposure is contributing to a growing prevalence of allergic conditions, including asthma, allergic rhinitis, and various skin allergies.
Urban populations are particularly at risk due to higher pollutant levels, which trigger immune reactions and create a need for early and precise diagnoses. The trend toward remote consultations and telehealth has enhanced access to diagnostic services, while diagnostic firms are broadening their test offerings to cover a wide range of environmental and food allergens. At the same time, increased awareness about allergies and government-supported awareness initiatives are driving greater demand for timely and accurate allergy diagnoses.
Allergy Diagnostics Regional Market Analysis
North America dominates the global allergy diagnostics market, with an estimated 45.4% share in 2024, driven by a high prevalence of allergic conditions, advanced diagnostic technologies, robust healthcare infrastructure, and strong public awareness. The United States remains the core contributor, supported by significant R&D investments, widespread adoption of in vitro and AI-driven diagnostics, and the presence of key players. Favorable reimbursement policies and growing demand for home testing kits further boost market growth. Conversely, the Asia-Pacific allergy diagnostics market is projected to record the fastest growth rate, at a CAGR of 11.8% during the forecast period 2024-2030.This growth is fueled by rapid urbanization, increasing pollution, and a rise in allergic cases. Countries like China, India, and Japan are expanding healthcare access, adopting advanced diagnostic tools, and investing in personalized and minimally invasive testing. Local firms are also implementing strategic initiatives to strengthen their regional presence. The digital transformation and increasing health consciousness are anticipated to drive market expansion in the Asia-Pacific region, making it a crucial area for growth.
Allergy Diagnostics Market Analysis by Product and Service
The consumables segment leads the allergy diagnostics market, capturing the largest share of 59.6% in 2024, and is anticipated to record the fastest CAGR of 11.2% from 2024 to 2030, driven by the recurring need for reagents, test kits, and other disposable supplies essential for routine and repetitive allergy testing. This segment benefits from cost efficiency, high-volume testing capacity, and ongoing technological advancements such as allergen microarray kits that enable personalized allergy profiling and continuous patient monitoring. Its affordability and continuous demand make it a consistent revenue stream across healthcare settings, including diagnostic labs and hospitals, where frequent replenishment is critical.Meanwhile, the instruments segment is projected to grow considerably, supported by advancements in automated systems, multiplex testing capabilities, and high diagnostic precision. Instruments like immunoassay analyzers, though more expensive, are increasingly adopted in diagnostic workflows because they offer faster and more accurate results. Their advanced testing capabilities improve operational efficiency, minimize human error, and support more comprehensive and effective allergy management.
Allergy Diagnostics Market Analysis by Test Type
In vitro testing is the largest segment in the allergy diagnostics market, accounting for a 53% share in 2024, and is anticipated to witness the fastest CAGR of 11.4% during the forecast period. This growth is attributed to its capacity to provide precise, standardized, and repeatable results without requiring direct allergen contact, which enhances safety for patients at high risk. These tests primarily identify allergen-specific immunoglobulin E (IgE), delivering excellent predictive value and specificity for sensitization to aeroallergens. The rising global incidence of food allergies further enhances the demand for in vitro diagnostics, given their accuracy and minimally invasive characteristics.The in vivo testing segment is also witnessing notable growth due to its user-friendliness, affordability, and quick results. Skin-prick tests (SPT) and intradermal tests are commonly used to detect immediate allergic reactions to various allergens such as pollen, dust mites, food, and insect venom. In vivo approaches act as an economical first-line screening option, particularly in price-sensitive markets, often succeeded by confirmatory in vitro assessments.
Allergy Diagnostics Market Analysis by Allergen Type
In 2024, the inhaled allergens segment holds the largest share of the allergy diagnostics market at 47%, driven by the increasing prevalence of respiratory conditions like allergic rhinitis, asthma, and chronic lung diseases. These conditions are triggered by airborne allergens such as pollen, mold spores, dust mites, and pet dander, which are becoming more widespread due to worsening environmental factors. The increasing levels of environmental pollution and industrialization intensify exposure to these inhaled allergens, resulting in a higher prevalence of respiratory allergies globally.The innovative Component-Resolved Diagnostics (CRD) technology enhances accuracy by pinpointing specific allergenic proteins, which minimizes cross-reactivity issues associated with tests using whole-allergen extracts. The growth of mold due to flooding and the dispersion of pollen during thunderstorms further increase incidents of respiratory allergies, underscoring the urgent requirement for accurate inhaled allergen diagnosis. In contrast, the food allergens segment is anticipated to experience the fastest CAGR of 11.8% during the analysis period 2024-2030. This growth is fueled by the rising incidence of food allergies, especially among children, and the growing demand for timely and accurate diagnostic solutions.
It is further supported by advancements in diagnostic technologies, heightened awareness among healthcare professionals and patients, and stricter food labeling regulations driven by concerns for food safety. Moreover, globalization and the increased consumption of processed foods heighten exposure risks, further driving the need for food allergen testing and contributing to the overall growth of the allergy diagnostics market.
Allergy Diagnostics Market Analysis by End-User
The hospitals and clinics segment holds a leading position in the allergy diagnostics market, with an estimated share of 44.9% in 2024, owing to their extensive healthcare services and access to advanced diagnostic technologies. These facilities act as primary care centers for patients facing allergic reactions, enabling accurate diagnosis and effective management. The increasing occurrence of severe allergic incidents like anaphylaxis, asthma attacks, and drug allergies boosts the demand for quick, in-house allergy testing, particularly in emergency and inpatient scenarios.Hospitals and clinics benefit from integrated patient care, high patient volume, advanced resources, and collaboration with allergists, ensuring diagnostic tests are timely, efficient, and precise. On the other hand, the academic research institutes segment is projected to experience the fastest growth rate at a CAGR of 11.5% from 2024 to 2030, fueled by an increased emphasis on translational research into new biomarkers, molecular allergens, and customized diagnostics. These institutions drive innovation in molecular diagnostics and next-generation sequencing, addressing the growing rates of allergies and developing new therapies and diagnostic methods to enhance patient outcomes and allergy management.
Allergy Diagnostics Market Report Scope
This global report on Allergy Diagnostics analyzes the market based on product and service, test type, allergen type, and end-user for the period 2021-2030 with projections from 2024 to 2030 in terms of value in US$. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.Key Metrics
Historical Period: 2021-2023Base Year: 2024
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 14+
Allergy Diagnostics Market by Geographic Region
- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World
Allergy Diagnostics Market by Product and Service
- Consumables
- Instruments
- Services
Allergy Diagnostics Market by Test Type
- In vitro Tests
- In vivo Tests
Allergy Diagnostics Market by Allergen Type
- Inhaled Allergens
- Food Allergens
- Drug Allergens
- Other Allergens (Including Contact Allergens, Insect Allergens and others)
Allergy Diagnostics Market by End-User Facility
- Hospitals and Clinics
- Diagnostic Laboratories
- Academic Research Institutes
- Other End-Users (Including Pharmaceutical and Biotech Companies)
This product will be delivered within 2-4 business days.
Table of Contents
PART A: GLOBAL MARKET PERSPECTIVE2. Key Market Trends3. Key Global Players4. Key Business, Product and Service TrendsREGIONAL MARKET OVERVIEWPART C: GUIDE TO THE INDUSTRYPART D: ANNEXURE1. RESEARCH METHODOLOGY2. FEEDBACK
1. INTRODUCTION
5. Global Market Overview
PART B: REGIONAL MARKET PERSPECTIVE
6. North America
7. Europe
8. Asia-Pacific
9. South America
10. Rest of World
Companies Mentioned
- bioMerieux SA
- Canon Medical Diagnostics USA
- Danaher Corporation
- Eurofins Scientific SE
- EUROIMMUN Medizinische Labordiagnostika AG
- HOB Biotech Group Corp., Ltd.
- Hycor Biomedical Inc.
- Lincoln Diagnostics, Inc.
- Neogen Corporation
- Omega Diagnostics Group PLC
- R-Biopharm AG
- Siemens Healthcare Diagnostics, Inc.
- Stallergenes Greer International AG
- Thermo Fisher Scientific Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 317 |
Published | June 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 5.8 billion |
Forecasted Market Value ( USD | $ 10.7 billion |
Compound Annual Growth Rate | 10.8% |
Regions Covered | Global |
No. of Companies Mentioned | 14 |